{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:21Z","timestamp":1790790681676,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the long-term efficacy and safety of brodalumab, a fully human anti\u2013interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients receiving subcutaneous brodalumab 210\u2009mg during the 16-week double-blind period of this multicentre, phase 3 study conducted across Japan, Korea and Taiwan continued the same during the 52-week open-label extension, whereas patients receiving placebo switched to brodalumab 210\u2009mg at week 16. Efficacy [Assessment of SpondyloArthritis International Society (ASAS) 40 and ASAS 20 response rates; change from baseline in AS Disease Activity Score using CRP (ASDAS-CRP)] and safety were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 145 patients (brodalumab, n\u2009=\u200977; placebo, n\u2009=\u200968) received brodalumab during the open-label extension. ASAS 40 response rates (95% CI) of 56.3% (44.7%, 67.3%) and 57.4% (44.1%, 70.0%) were achieved in the brodalumab and placebo groups, respectively, at week 68. ASAS 20 response rates (95% CI) achieved at week 68 in both treatment groups were similar [brodalumab, 71.3% (60.0%, 80.8%); placebo, 78.7% (66.3%, 88.1%)]. The least squares mean change (95% CI) in ASDAS-CRP at week 68 suggested a clinically important improvement (change, \u22651.1) in both treatment groups [brodalumab, \u20131.528 (\u20131.737, \u20131.319); placebo, \u20131.586 (\u20131.815, \u20131.357)]. The exposure-adjusted event rates (per 100 patient-years) for treatment-emergent adverse events (TEAEs) and drug-related TEAEs were 255.9 and 147.9, respectively; nasopharyngitis (35.6) and upper respiratory tract infection (14.7) were the most common TEAEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Brodalumab demonstrated sustained efficacy and a consistent safety profile in patients with axSpA over 68\u2009weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT02985983<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac522","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T21:22:41Z","timestamp":1663795361000},"page":"1851-1859","source":"Crossref","is-referenced-by-count":15,"title":["Brodalumab, an anti\u2013interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-2276","authenticated-orcid":false,"given":"Tae-Hwan","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases , Seoul, The Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital , Taichung, Taiwan"},{"name":"Institute of Medicine, College of Medicine, Chung Shan Medical University , Taichung, Taiwan"},{"name":"Graduate Institute of Integrated Medicine, China Medical University , Taichung, Taiwan"},{"name":"Department of Medical Research, Taichung Veterans General Hospital , Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeyoun","family":"Jeong","sequence":"additional","affiliation":[{"name":"Clinical Development Team, Medical Department, Kyowa Kirin Korea Co., Ltd , Seoul, The Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyo","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Clinical Development Center, R&D Division, Kyowa Kirin Co., Ltd , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University Koshigaya Hospital , Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"2023050208173538200_keac522-B1","doi-asserted-by":"crossref","first-page":"ii43","DOI":"10.1093\/rheumatology\/kew346","article-title":"Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases","volume":"55","author":"Nirula","year":"2016","journal-title":"Rheumatology"},{"key":"2023050208173538200_keac522-B2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2023050208173538200_keac522-B3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"2023050208173538200_keac522-B4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","article-title":"The classification and diagnostic criteria of ankylosing spondylitis","volume":"48\u201349","author":"Raychaudhuri","year":"2014","journal-title":"J Autoimmun"},{"key":"2023050208173538200_keac522-B5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023050208173538200_keac522-B6","first-page":"883","article-title":"Scoring with the Berlin MRI method for assessment of spinal inflammatory activity in patients with ankylosing spondylitis: a calibration exercise among rheumatologists","volume":"31","author":"Carmona","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2023050208173538200_keac522-B7","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023050208173538200_keac522-B8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR axial spondyloarthritis treatment recommendations","volume":"22","author":"Tam","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2023050208173538200_keac522-B9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/1756-185X.13094","article-title":"Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies","volume":"20","author":"Wei","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2023050208173538200_keac522-B10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/14397595.2018.1538004","article-title":"Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)","volume":"30","author":"Kishimoto","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023050208173538200_keac522-B11","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"2023050208173538200_keac522-B12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023050208173538200_keac522-B13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023050208173538200_keac522-B14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2023050208173538200_keac522-B15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology"},{"key":"2023050208173538200_keac522-B16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023050208173538200_keac522-B17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023050208173538200_keac522-B18","first-page":"s29","article-title":"What lies beneath the face value of a BOX WARNING: a deeper look at brodalumab","volume":"17","author":"Hashim","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"2023050208173538200_keac522-B19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023050208173538200_keac522-B20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.36849\/JDD.2020.5138","article-title":"One-year pharmacovigilance update of brodalumab","volume":"19","author":"Lebwohl","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"2023050208173538200_keac522-B21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/09546634.2013.826341","article-title":"Biologic fatigue in psoriasis","volume":"25","author":"Levin","year":"2014","journal-title":"J Dermatolog Treat"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac522\/46340403\/keac522.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/5\/1851\/50120865\/keac522.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/5\/1851\/50120865\/keac522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T08:23:21Z","timestamp":1683015801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/5\/1851\/6709339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,21]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac522","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,9,21]]}}}